A recent study indicates that patients who discontinue blockbuster slimming jabs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who end traditional diet and exercise plans.
Published data in a major medical journal shows that while overweight people frequently drop a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying such medications must be informed of the potential of quick weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight within about 18 months.
Comparing Therapies
The analysis, which looked at dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Researchers emphasize that people who lose weight through dieting usually have a slower creep back—around 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists believe the mechanism of the injections explains the heightened regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than normal might result in the body to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Issue?
The NHS suggest the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals contend that, considering the likelihood of weight regain, the therapy should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the long-term nature of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Individuals who have come off the jabs report a intense return of appetite.
"I experienced something flipping and I was suddenly extremely hungry," recalled one woman.
The struggle is exacerbated if users have not developed sustainable dietary or behavioural changes during therapy.
Growing Use
Survey data indicate that millions of people in the UK have used these injections in the past year, with demand remaining high.
- Use is greater among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing behavioural management.
